Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rociletinib + Atezolizumab in EGFRm NSCLC
NCT02630186Phase 2Terminated
- Sponsor
- Clovis Oncology
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rociletinib in non-small cell lung cancer (NSCLC), sponsored by Clovis Oncology. Started Feb 2016; status: terminated.
02
Drugs
rociletinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02630186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630186.